The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma
Abstract
Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment. The present study was a multicenter RCT aimed to compare the outcomes of percutaneous cryoablation with RFA for the treatment of HCC. In all, 360 patients with Child‐Pugh class A or B cirrhosis and one or two HCC lesions ≤ 4 cm, treatment‐naïve, without metastasis were randomly assigned to cryoablation (n = 180) or RFA (n = 180). The primary endpoints were local tumor progression at 3 years after treatment and safety. Local tumor progression rates at 1, 2, and 3 years were 3%, 7%, and 7% for cryoablation and 9%, 11%, and 11% for RFA, respectively (P = 0.043). For lesions >3 cm in diameter, the local tumor progression rate was significantly lower in the cryoablation group versus the RFA group (7.7% versus 18.2%, P = 0.041). The 1‐, 3‐, and 5‐year overall survival rates were 97%, 67%, and 40% for cryoablation and 97%, 66%, and 38% for RFA, respectively (P = 0.747). The 1‐, 3‐, and 5‐year tumor‐free survival rates were 89%, 54%, and 35% in the cryoablation group and 84%, 50%, and 34% in the RFA group, respectively (P = 0.628). Multivariate analyses demonstrated that Child‐Pugh class B and distant intrahepatic recurrence were significant negative predictors for overall survival. Major complications occurred in seven patients (3.9%) following cryoablation and in six patients (3.3%) following RFA (P = 0.776). Conclusion: Cryoablation resulted in a significantly lower local tumor progression than RFA, although both cryoablation and RFA were equally safe and effective, with similar 5‐year survival rates. (H epatology 2015;61:1579–1590)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria
Goldberg, S. N., Grassi, C. J., Cardella, J. F., Charboneau, J. W., Dodd, G. D., Dupuy, D. E., Gervais, D., Gillams, A. R., Kane, R. A., Lee, F. T., et al. (2005) · Radiology · doi:10.1148/radiol.2353042205 · Cited by 1,193
Lin, S.-M., Lin, C.-J., Lin, C.-C., Hsu, C.-W., & Chen, Y.-C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.003 · Cited by 609
Local-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Loco‐regional treatment of hepatocellular carcinoma†
Lencioni, R. (2010) · Hepatology · doi:10.1002/hep.23725 · Cited by 509
Hepatocellular carcinoma in the Asia pacific region
Yuen, M., Hou, J., & Chutaputti, A. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05784.x · Cited by 427
Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies
Pearson, A. S., Izzo, F., Fleming, R. Y. D., et al. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00234-2 · Cited by 372
Stigliano, R., Marelli, L., Yu, D., Davies, N., Patch, D., & Burroughs, A. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.001 · Cited by 311
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Doyle, A., Gorgen, A., Muaddi, H., Aravinthan, A. D., Issachar, A., Mironov, O., Zhang, W., Kachura, J., Beecroft, R., Cleary, S. P., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.027 · Cited by 148
Metadata
- Authors
- Wang, C., Wang, H., Yang, W., Hu, K., Xie, H., Hu, K., Bai, W., Dong, Z., Lu, Y., Zeng, Z., Lou, M., Wang, H., Gao, X., Chang, X., An, L., Qu, J., Li, J., & Yang, Y.
- Venue
- Hepatology
- Published
- 2015-03-20
- Volume
- 61
- Issue
- 5
- Pages
- 1579-1590
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1548590980
- Cited by
- 272
- References
- 18
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1002/hep.27548
- The paper
- Wang, C., Wang, H., Yang, W., Hu, K., Xie, H., Hu, K., Bai, W., Dong, Z., Lu, Y., Zeng, Z., Lou, M., Wang, H., Gao, X., Chang, X., An, L., Qu, J., Li, J., & Yang, Y. (2015). Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. https://doi.org/10.1002/hep.27548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
